anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

All filtered slides

Global slide inventory for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Corpus coverage

319,975 slides

319,974 are described (100%), so the treemap can explain the corpus instead of just counting files.

Total slides
319,975
Described
319,974
Pending
1

Slide type composition

dynamicclickable
Slide type

Showing 319,974 described slides — 100.0% of 319,975 rendered pages

+Context & problem43,76713.7% · 6,592 docs+Data & charts72,62022.7% · 8,666 docs+Meta & navigation45,93614.4% · 9,739 docs+Recommend & act67,04121.0% · 9,324 docs+Cases & evidence31,2569.8% · 6,067 docs+Frameworks2,1230.7% · 1,232 docs+Appendix35,68211.2% · 6,614 docs+Other21,5496.7% · 5,566 docs

Tile area is proportional to slide count. Click a category to open its subtype map.

all document kinds · all orientations
18 30 60

Slide collection

226,501-226,560 of 319,975

filter-aware
15
The slide uses a combination of a bar-line chart for historical trends and a waterfall chart for the quarterly bridge.New York Community Bancorp | Results Presentation Deck | 42 slides · New York Community Bancorp
Conference presentation Investor relations Beat · FinancialsLoop · Cost Of Inaction1 hit
16
The chart highlights NYCB's generally lower non-performing loan ratios compared to the broader market index over the observed period.New York Community Bancorp | Results Presentation Deck | 42 slides · New York Community Bancorp
Conference presentation Investor relations Beat · FinancialsLoop · Cost Of Inaction1 hit
17
The chart highlights a significant spike in charge-offs for the S&P index during the 2008-2012 period compared to NYCB.New York Community Bancorp | Results Presentation Deck | 42 slides · New York Community Bancorp
Conference presentation Investor relations Beat · FinancialsLoop · Cost Of Inaction1 hit
18
The chart uses a dashed line to represent the peer median of 0.55%.New York Community Bancorp | Results Presentation Deck | 42 slides · New York Community Bancorp
Conference presentation Investor relations Beat · FinancialsLoop · Cost Of Inaction1 hit
19
The slide highlights that NYCB remains well-capitalized despite ongoing goodwill impairment assessments.New York Community Bancorp | Results Presentation Deck | 42 slides · New York Community Bancorp
Conference presentation Investor relations Beat · FinancialsLoop · Cost Of Inaction1 hit
20
The slide highlights NYCB's relative capital position using two different metrics (Adjusted vs Reported).New York Community Bancorp | Results Presentation Deck | 42 slides · New York Community Bancorp
Conference presentation Investor relations Beat · FinancialsLoop · Cost Of Inaction1 hit
21
The map highlights specific states (CA, AZ, WI, MI, IN, OH, NJ, NY, FL) where the bank has a physical presence.New York Community Bancorp | Results Presentation Deck | 42 slides · New York Community Bancorp
Conference presentation Investor relations Beat · Solution1 hit
22
The slide displays a pie chart of loan distribution and a list of portfolio highlights including yield, historical losses, and criticized loan increases.New York Community Bancorp | Results Presentation Deck | 42 slides · New York Community Bancorp
Conference presentation Investor relations Beat · Solution1 hit
23
Includes data on origination and net charge-offs alongside portfolio composition metrics.New York Community Bancorp | Results Presentation Deck | 42 slides · New York Community Bancorp
Conference presentation Investor relations Beat · Solution1 hit
24
The table segments the portfolio by percentage of rent-regulated units, showing loan counts, balances, unit counts, LTV, and DSCR.New York Community Bancorp | Results Presentation Deck | 42 slides · New York Community Bancorp
Conference presentation Investor relations Beat · Solution1 hit
25
Data presented as of 4th Quarter 2023.New York Community Bancorp | Results Presentation Deck | 42 slides · New York Community Bancorp
Conference presentation Investor relations Beat · Solution1 hit
26
UPB stands for Unpaid Principal Balance.New York Community Bancorp | Results Presentation Deck | 42 slides · New York Community Bancorp
Conference presentation Investor relations Beat · Solution1 hit
27
Includes footnotes regarding DSCR and LTV calculations.New York Community Bancorp | Results Presentation Deck | 42 slides · New York Community Bancorp
Conference presentation Investor relations Beat · Solution1 hit
28
The slide uses a combination of text, a dual-axis line chart, a choropleth map, and a stacked bar chart to illustrate business performance and market context.New York Community Bancorp | Results Presentation Deck | 42 slides · New York Community Bancorp
Conference presentation Investor relations Beat · Solution1 hit
29
Includes a footnote referencing page 30 for additional Warehouse information.New York Community Bancorp | Results Presentation Deck | 42 slides · New York Community Bancorp
Conference presentation Investor relations Beat · Solution1 hit
30
Includes a stacked bar chart for commitments, a table for market share, and a pie chart for collateral breakdown.New York Community Bancorp | Results Presentation Deck | 42 slides · New York Community Bancorp
Conference presentation Investor relations Beat · Solution1 hit
31
New York Community Bancorp | Results Presentation Deck | 42 slidesNew York Community Bancorp | Results Presentation Deck | 42 slides · New York Community Bancorp
Conference presentation Investor relations 1 hit
32
Includes total dollar amounts and key portfolio characteristics.New York Community Bancorp | Results Presentation Deck | 42 slides · New York Community Bancorp
Conference presentation Investor relations 1 hit
33
Includes four charts showing quarterly trends from Dec 2022 to 4Q23.New York Community Bancorp | Results Presentation Deck | 42 slides · New York Community Bancorp
Conference presentation Investor relations 1 hit
34
The slide presents data across five quarters for various metrics, including MSR portfolio statistics, net return components, and loan servicing volumes.New York Community Bancorp | Results Presentation Deck | 42 slides · New York Community Bancorp
Conference presentation Investor relations 1 hit
35
Includes SBNY acquisition impact and prior acquisitions.New York Community Bancorp | Results Presentation Deck | 42 slides · New York Community Bancorp
Conference presentation Investor relations 1 hit
36
The slide presents specific quantitative targets for FY2024.New York Community Bancorp | Results Presentation Deck | 42 slides · New York Community Bancorp
Conference presentation Investor relations Beat · Guidance1 hit
37
The chart illustrates the transition from $2,088M in 2023 to $2,353M in 2024.New York Community Bancorp | Results Presentation Deck | 42 slides · New York Community Bancorp
Conference presentation Investor relations Beat · Guidance1 hit
38
The slide defines Category IV banks as publicly traded US-based banks with assets >$100 billion and <$250 billion in total assets.New York Community Bancorp | Results Presentation Deck | 42 slides · New York Community Bancorp
Conference presentation Investor relations 1 hit
39
Includes a footnote regarding merger-related items.New York Community Bancorp | Results Presentation Deck | 42 slides · New York Community Bancorp
Conference presentation Investor relations 1 hit
40
Includes two distinct tables: one for income/EPS reconciliation and one for allowance coverage ratio.New York Community Bancorp | Results Presentation Deck | 42 slides · New York Community Bancorp
Conference presentation Investor relations 1 hit
41
Includes reconciliations for equity, assets, and various return ratios.New York Community Bancorp | Results Presentation Deck | 42 slides · New York Community Bancorp
Conference presentation Investor relations 1 hit
42
New York Community Bancorp | Results Presentation Deck | 42 slidesNew York Community Bancorp | Results Presentation Deck | 42 slides · New York Community Bancorp
Conference presentation Investor relations 1 hit
01
Slide 1
Includes company logo, date, and tagline.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
02
Nuvalent | Investor Presentation Deck | 42 slidesNuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
03
The slide uses a 2x2 grid layout to summarize key company metrics.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
04
The slide uses a list of four key pillars of the company's methodology.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations Beat · Solution1 hit
05
The slide uses a chronological structure to demonstrate operational momentum.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations Beat · Solution1 hit
06
The slide uses a timeline to connect corporate strategy to specific clinical trial milestones.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations Beat · Solution1 hit
07
The slide features a split layout with a left-hand column for advisors/board and a right-hand grid for the leadership team, plus a footer highlighting 12 prior FDA approvals.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations Beat · Solution1 hit
08
The slide uses a Gantt-style visualization to represent drug development stages.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations Beat · Solution1 hit
09
The slide uses a structured table to contrast two distinct patient populations (ALK+ vs ROS1+) across three lines of therapy (1L, 2L, 3L+).Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
10
Uses a 'cite_precedent' framework to validate the strategy by comparing it to the established success of Osimertinib.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
11
The chart visualizes the dominance of Alectinib and Crizotinib in the current market landscape.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations Beat · Market SizingLoop · Cost Of Inaction1 hit
12
Slide 12 of a pitch deck, likely from Nuvalent.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations Loop · Jobs To Be Done1 hit
13
The slide uses a timeline-based journey map to contrast standard treatments with unmet clinical needs.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations Loop · Jobs To Be Done1 hit
14
The slide uses a matrix-style comparison to highlight the superior/differentiated profile of the 4th generation inhibitor NVL-655.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations Loop · Jobs To Be Done1 hit
15
The slide presents two distinct scientific data sets: an IC50 dot plot for in vitro activity and a bar chart for in vivo tumor regression.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
16
Includes a formula for Selectivity index and a legend for various compound mutations.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
17
The slide provides a detailed breakdown of patient enrollment across different dose cohorts (15mg to 200mg QD) for the NVL-655 clinical trial.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
18
Data cut-off: 8 Aug 2023. Includes detailed breakdown of prior ALK TKI therapies.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
19
Slide presents two distinct clinical data visualizations: a PK line chart and a waterfall plot for mutation clearance.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
20
Data cut-off: 8 Aug 2023. Includes detailed breakdown of response by mutation type and prior treatment history.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
21
Clinical trial data (ALKove-1) showing efficacy of NVL-655 in NSCLC patients.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
22
Swimmer plot visualization of clinical trial patient outcomes.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
23
Includes before/after MRI scans for two specific patient cases.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
24
Data cut-off: 8 Aug 2023. N=93 treated patients.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
25
The slide uses a three-column layout to segment the market by treatment line (3L+, 2L, 1L) and contrast current standards of care with the proposed solution's benefits.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
26
The slide outlines a clinical trial design with specific patient cohorts (2a-2d) and study objectives.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
27
The slide uses a sidebar 'AT A GLANCE' to summarize key program attributes.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
28
The slide uses a timeline-based framework to contrast 1L and 2L+ treatment landscapes and their associated clinical challenges.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
29
The slide uses a matrix-like comparison to highlight the unique value proposition of NVL-520 compared to standard-of-care drugs.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
30
Includes specific pharmacological data points for NVL-520 vs competitors like Crizotinib, Entrectinib, Lorlatinib, Taletrectinib, and Repotrectinib.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
31
The slide presents a summary of a clinical trial, including patient eligibility criteria and a breakdown of patient enrollment by dose cohort.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
32
Data presented in two side-by-side tables summarizing patient characteristics and treatment history.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit